WASHINGTON, May 26, 2016 /PRNewswire/ --
TARE
(Transarterial
Radio-embolization) Using
Yttrium-90 Glass
Microspheres, Associated
With Both Cost
Savings and Overall Decreased
Use of Hospital Resource
BTG plc (LSE: BTG), an international specialist healthcare
company, has today announced the publication of new data at the
21st Annual Meeting of ISPOR (International Society for
Pharmacoeconomics and Outcomes Research), highlighting that
treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass
microspheres is associated with cost savings and decreased hospital
resource use.
(Logo:
http://photos.prnewswire.com/prnh/20160203/329110LOGO )
The results of the budget impact analysis, undertaken from a
Canadian hospital perspective, show that for a Canadian hospital
managing 200 HCC patients annually, reimbursing TARE (transarterial
radio-embolization) would incur savings of approximately
$37,000, $55,000 and $75,000
in years one, two and three respectively. In year three, the
analysis includes incremental costs of $207,000 for device acquisition compared against
savings of $281,000 for
administration and savings of $1,000
in adverse event management.
Commenting on the results, study author Marie Maxime Hubert, from JSS Medical Research
Inc., said, "For patients with HCC, at either intermediate or
advanced stages, TARE has the potential to improve survival, has a
favorable safety profile and has seen successful outcomes in
patients with portal vein thrombosis (PVT). In the context of
increasingly cost-pressured health systems around the world, the
potential for TARE to improve patient outcomes while at the same
time support hospitals' management of scarce resources should not
be underestimated."
The budget impact analysis applied for the study used the
Ontario Case Costing Initiative database, published literature and
expert opinion to determine the potential for cost savings from a
Canadian hospital perspective. It compared the treatment of
intermediate HCC with TARE using yttrium-90 glass microspheres,
versus TACE, an inpatient procedure, including cTACE and
drug-eluting beads TACE (DEB-TACE). In patients with advanced HCC,
TARE was compared to self-administered sorafenib.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing
international specialist healthcare company. As medicine moves from
major surgery to minor procedure, from the systemic to the local,
no company endeavors to do more than BTG Interventional Medicine to
help doctors in their quest to see more, reach further and treat
smarter. Our growing portfolio of Interventional Medicine products
is designed to advance the treatment of liver tumors, advanced
emphysema, severe blood clots, and varicose veins. To learn more
about BTG Interventional Medicine, please visit: btg-im.com.
About TheraSphere®
TheraSphere® 90Y glass microspheres are
specifically engineered to carry far greater power than any other
90Y liver-directed cancer therapy, delivering high doses
of radiation to liver tumors while sparing normal tissue. The
result is a powerful, targeted and well-tolerated therapy that may
lead to patients becoming eligible for curative therapies.
In the US, TheraSphere® is FDA approved under a
Humanitarian Device Exemption (HDE) for the treatment of
hepatocellular carcinoma (HCC). In the EU, TheraSphere®
is CE Marked for the treatment of hepatic neoplasia. In
Canada, TheraSphere®
may be used in the treatment of hepatic neoplasia in patients who
have appropriately positioned arterial catheters.
For full instructions for use and important safety information,
please visit www.therasphere.com.
SOURCE BTG plc
